Plathet rich plasma

PreclinicalBiologic

HHospital Italiano de Buenos Aires

Plathet rich plasma is one of 23 biologic programs targeting Tendinopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TendinopathyActive, not recruiting

TendinopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Tendinopathy

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Arcoxia

Novartis

Approved

1 3

Cosentyx

Novartis

Phase 3

4 4

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—5

Kenalog

BBausch Health Americas, Inc.

Phase 3

1 6

Restasis

TTaiwan Bio Therapeutics Inc.

Whole Blood

1 8

Ketalar

HHelse Møre og Romsdal HF

Phase 3

1 9

Genotropin

EMD Serono

Phase 2

1 10

Xylocaine

MMEDRx USA, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tendinopathy1 trial

Comparison Between Platelet Rich Plasma and Corticosteroids for the Treatment of Rotator Cuff Tendinopathy

Completed·HHospital Italiano de Buenos Aires·N/A·NCT06150378·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Plathet rich plasma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plathet rich plasma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plathet rich plasma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Italiano de Buenos Aires company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHospital Italiano de Buenos Aires

Plathet rich plasma

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tendinopathy1 trial

References

Drug Info

Quick Facts

Related News